-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Purulent sweat adenitis (HS) is a chronic inflammatory skin disease that mainly affects the armpits, groin, anal, pubic and lower breast areas.
its clinical manifestations vary, the light manifestations are relapsed inflammatory nodules and abscesses, in severe cases can form drainage sinus channels and severe strip-like scars.
, odors, secretions and appearance damage associated with HS have severe psychosocial effects on many patients.
pharmaceutical company Chemo Centryx announced today that a randomized, double-blind, placebo-controlled, multicenter Phase II clinical trial of the oral supplement C5a-subject selective inhibitor Avacopan treats septic sweat adenitis (HS) with positive topline data.
phase II clinical trial randomly assigned 398 patients to three treatment groups (10 mg Avacopan, 30 mg Avacopan, placebo).
study population included patients with moderate HS (Hurley II) or severe HS (Hurley III) who were equally distributed among the treatment groups.
end of the treatment was the proportion of patients who had reached the clinical response to purulent sweat adenitis (HiSCR) after 12 weeks of treatment.
results showed that patients in the 30 mg avacopan group had a statistically higher response than placebos in Hurley III (severe) HS patients.
: HiSCR results
